Department of Dermatology, Taipei City Hospital, Taipei City, Taiwan; Department of Dermatology, National Taiwan University Hospital and College of Medicine, Taipei City, Taiwan; School of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei City, Taiwan.
Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan; Center for General Education, Lee-Ming Institute of Technology, New Taipei City, Taiwan.
J Am Acad Dermatol. 2023 Sep;89(3):496-503. doi: 10.1016/j.jaad.2023.05.037. Epub 2023 May 24.
UV-B phototherapy is a common treatment modality for patients with atopic dermatitis (AD), but its long-term safety in terms of cutaneous carcinogenic risk has not been studied.
To investigate the risk of skin cancer among patients with AD receiving UV-B phototherapy.
We conducted a nationwide population-based cohort study from 2001 to 2018 to estimate the risk of UV-B phototherapy for skin cancer, nonmelanoma skin cancer, and cutaneous melanoma in patients with AD.
Among 6205 patients with AD, the risks of skin cancer (adjusted hazard ratio [HR], 0.91; 95% CI, 0.35-2.35), nonmelanoma skin cancer (adjusted HR, 0.80; 95% CI, 0.29-2.26), and cutaneous melanoma (adjusted HR, 0.80; 95% CI, 0.08-7.64) did not increase among patients with AD treated with UV-B phototherapy, compared with those who did not receive UV-B phototherapy. Additionally, the number of UV-B phototherapy sessions was not associated with an increased risk of skin cancer (adjusted HR, 0.99; 95% CI, 0.96-1.02), nonmelanoma skin cancer (adjusted HR, 0.99; 95% CI, 0.96-1.03), or cutaneous melanoma (adjusted HR, 0.94; 95% CI, 0.77-1.15).
Retrospective study.
Neither UV-B phototherapy nor the number of UV-B phototherapy sessions was associated with an increased risk of skin cancers among patients with AD.
UV-B 光疗是特应性皮炎（AD）患者的常见治疗方式，但尚未研究其在皮肤致癌风险方面的长期安全性。
研究接受 UV-B 光疗的 AD 患者罹患皮肤癌的风险。
我们开展了一项 2001 年至 2018 年的全国性基于人群的队列研究，以评估 AD 患者接受 UV-B 光疗与皮肤癌、非黑素瘤皮肤癌和皮肤黑色素瘤的相关性。
在 6205 例 AD 患者中，与未接受 UV-B 光疗的患者相比，接受 UV-B 光疗的患者罹患皮肤癌（校正危害比 [HR]，0.91；95%CI，0.35-2.35）、非黑素瘤皮肤癌（校正 HR，0.80；95%CI，0.29-2.26）和皮肤黑色素瘤（校正 HR，0.80；95%CI，0.08-7.64）的风险并未增加。此外，UV-B 光疗次数与皮肤癌（校正 HR，0.99；95%CI，0.96-1.02）、非黑素瘤皮肤癌（校正 HR，0.99；95%CI，0.96-1.03）或皮肤黑色素瘤（校正 HR，0.94；95%CI，0.77-1.15）风险的增加无关。
回顾性研究。
UV-B 光疗和 UV-B 光疗次数均与 AD 患者罹患皮肤癌的风险增加无关。
